Granules Hyderabad facility gets 11 FDA observations after inspection
In short
Granules’ Hyderabad finished-dosage facility got 11 observations from the U.S. FDA after an inspection that ran from October 19 to October 30. The company said the inspection does not affect manufacturing or product distribution.
This matters because FDA findings can affect a drug plant’s compliance status, but the report does not say how serious the observations are. It also does not say what the company must do next.
What the reporting says
Granules’ finished dosage facility in Hyderabad received 11 U.S. FDA observations after an inspection conducted from October 19 to October 30. The published summaries also say the FDA issued a warning letter in February 2025 after inspecting the site in August–September 2024, while the company said there is no impact on manufacturing or distribution. The reporting does not state what the observations were or whether any remediation timeline was given.
Why it matters
Granules’ Hyderabad finished-dosage site was inspected by the U.S. FDA from October 19 to October 30, and the inspection resulted in 11 observations. Separate summary material says the FDA had also issued a warning letter in February 2025 after an earlier inspection in August–September 2024. The company said manufacturing and distribution are not affected, but the reporting does not provide the specific findings or next steps.